CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
What is Cancer
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Cellular Oncogenes
Tumor Suppressor Genes
History and Growth of the Cancer Treatment Market
Industry Structure
Product Segments and Technology
Chemotherapy: At a Glance
Hormone Therapy: At A Glance
Biotherapy: At A Glance
Radiation Therapy: At a Glance
Demographics and Statistics
Global Cancer Statistics
Demographics
Aging Population
Life Expectancy and Cancer
Life Expectancy
Birth Rates
Description of Cancers
Bladder Cancer
Brain Cancer
Glioblastoma
Neuroblastoma
Breast Cancer
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Head and Neck
Kidney
Leukemia
Liver
Lung Cancer
Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Pancreas
Prostate Cancer
Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
Overview
Product Descriptions and Examples
Alkylating Agents
Antimetabolites
Cytotoxic Agents
Plant Derivatives
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
European Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
Overview
Product Descriptions and Examples
Corticosteroids
Hormone Agonists and Antagonists
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS
Overview
Product Descriptions and Examples
Monoclonal Antibodie
Interleukins/Interferons
Tyrisoine Kinase Inhibitors
Other Biotherapeutics
Radioimmunotherapy
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
Overview
Total Market Size and Forecast
Geographical Market Distribution
Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Introduction
Insurance and Reimbursement Issues
Cancer Drug Costs
Personalized Medicine
Targeted Cancer Therapy
Pharmacogenomics
Alliances Acquisitions and Licensing Agreements
Patient-Reported Outcomes
Alcohol’s Affect on Cancer Incidence
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
Obesity in the U.S.
U.S. Obesity Rates Differ Among Ethnic Groups
Outlook for a Healthier U.S. Population
Cancer Trends
Marketing and Distribution Trends
Geographical Trends
United States
Europe
Japan
Elderly Clinical Trial Involvement
Late-Stage Drug Development Trends
Significant Developments
Alpharadin
Afatinib
Axitinib
Bosutinib
Brentuximab
Carfilzomib
Crizotinib
Erwinaze
Exelbine
Motesanib
Omnitarg
Regorafenib
Ridaforolimus
Zaltrap
Recent NDA Activity
New Approvals
CHAPTER EIGHT: CORPORATE PROFILES
Introduction
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly & Company
Johnson & Johnson
Merck & Company, Inc.
Novartis AG
Pfizer, Inc.
Roche
Sanofi
APPENDIX: MAJOR COMPETITOR DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: World Cancer Market
Table 1-2: Market by Product Type (Chemotherapy, Hormone Therapy, Biotherapeutics), 2005-2015
Figure 1-1: World Cancer Market, Market by Product Type (Chemotherapy, Hormone Therapy, Biotherapeutics), 2005-2015
Figure 1-2: World Cancer Market, Market by Product Type and Percent Market Share, 2010
CHAPTER TWO: INTRODUCTION
Table 2-1: Viruses Associated with Cancer in Humans
Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
Table 2-2: World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, (Lung,Breast, Colon/ Rectum, Stomach, Liver, Prostate, Cervical, Ovarian, Lymphoma, Pancreatic, Melanoma)
Figure 2-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-3: Total Cancer Incidence by Sex and Country(Canada, China, France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom, United States), 2010 Estimates
Figure 2-3: Total Cancer Incidence by Sex and Country(Canada, China, France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom, United States), 2010 Estimates
Table 2-4: World Population by Selected Geographical Region(Africa, Asia, Europe, North America, Oceania, South America, World), 2010 - 2050
Figure 2-4: World Population by Selected Geographical Region(Africa, Asia, Europe, North America, Oceania, South America, World), 2010-2050
Table 2-5: Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-5: Estimated World Population by Age, 2010 and 2050
Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2009
Figure 2-6: Average Life Expectancy in Years by Country 1980 and 2009
Figure 2-7: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2006
Figure 2-8: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
Table 2-7: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Figure 2-9: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Table 2-9: Types of Leukemia
Table 2-9: Types of Primary Lung Cancer
Table 2-10: Classification of Non-Hodgkin’s Lymphomas
Table 2-11: Malignant Conditions of the Skin
CHAPTER THREE: CHEMOTHERAPY
Table 3-1: Leading Products, 2010
Table 3-2: World Chemotherapy Market, 2005-2015
Figure 3-1: World Chemotherapy Market, 2005-2015
Table 3-3: World Chemotherapy Market, Sales by Drug Classification, (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives) 2010
Figure 3-2: World Chemotherapy Market by Drug Classification, (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives)
Table 3-4: World Chemotherapy Market, Sales by Drug Classification (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2010)
Figure 3-3: World Chemotherapy Market by Drug Classification (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2015
Figure 3-4: World Chemotherapy Current Market by Region (US, EU, Japan, ROW)
Figure 3-5: World Chemotherapy Market by Region 2015 (US, EU, Japan, ROW)
Table 3-5: World Chemotherapy Market Type by Cancer Type (Lung, Breast, Colon, Brain, Ovarian, Other Total)
Figure 3-6: World Chemotherapy Market by Cancer Type (Lung, Breast, Colon, Brain, Ovarian, Other Total)
Table 3-6: World Chemotherapy Market, Leading Suppliers Shares by Market Revenues, 2010
Figure 3-7: World Chemotherapy Market, Leading Suppliers Market Share, 2010
CHAPTER FOUR: HORMONE THERAPY
Table 4-1: Leading Products, 2010
Table 4-2: World Hormone Therapy Market, 2005-2015
Figure 4-1: World Hormone Therapy Market, 2005-2015
Table 4-3: World Hormone Therapy Market, Sales by Drug Classification ( Corticosteroids, Hormone agonists/ Antagonists, Aromatase Inhibitors, SERMs), 2010
Figure 4-2: World Hormone Therapy Market, Market by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs) and Percent Market Share, 2010
Table 4-4: World Hormone Therapy Market, Sales by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors , SERMs), Estimated 2015
Figure 4-3: World Hormone Therapy Market, Market by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs) and Percent Market Share, 2015
Figure 4-4: World Hormone Therapy Current Market by Region (US, EU, Japan, ROW)
Figure 4-5: World Hormone Therapy Market by Region 2015 (US, EU, Japan, ROW)
Table 4-5: World Hormone Therapy Market by Cancer Type (Breast, Prostate, Other)
Figure 4-6: World Hormone Therapy Market by Cancer Type (Breast, Prostate, Other)
Table 4-6: World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2010
Figure 4-7: World Hormone Therapy Market, Leading Suppliers Market Share, 2010
CHAPTER FIVE: BIOTHERAPEUTICS
Table 5-1: Leading Biopharmaceutical Cancer Treatment Products (Brand Name, Generic Name, Manufacturer/ Marketer, Common Uses, Annual Sales ), 2010
Table 5-2: World Cancer Biotherapeutics Market, 2005-2015
Figure 5-1: World Cancer Biotherapeutics Market, 2005-2015
Table 5-3: World Biotherapeutics Market, Sales by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), 2010
Figure 5-2: World Biotherapeutics Market by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics)
Table 5-4: World Biotherapeutics Market, Sales by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), Estimated 2015
Figure 5-3: World Biotherapeutics Market by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), Estimated 2015
Figure 5-4: World Cancer Biotherapeutics Market by Region (US, EU, Japan, ROW)
Figure 5-5: World Cancer Biotherapeutics Market by Region (US, EU, Japan, ROW) , Estimated 2015
Table 5-5: World Cancer Biotherapeutics Market by Cancer Type (Colon, Breast, Lymphoma, Leukemia, Others)
Figure 5-6: World Cancer Biotherapeutics Market by Cancer Type(Colon, Breast, Lymphoma, Leukemia, Others)
Table 5-6: World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2010
Figure 5-7: World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2010
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
Table 6-1: World Cancer Market, Market by Product Type, 2005-2015
Figure 6-1: World Cancer Market, Market by Product Type Revenues, 2005-2015
Figure 6-2: World Cancer Market, Market by Product Type and Percent Market Share, 2010
Figure 6-3: World Cancer Market, Market by Product Type and Percent Market Share, 2015
Table 6-2: World Cancer Market, Leading Suppliers’ Shares by Market Revenues, 2010
Figure 6-5: World Cancer Market, Leading Suppliers’ Market Share, 2010
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Table 7-1: Obesity Rates by U.S. State, 2009
Table 7-2: Select Products in Development by Development Phase
Figure 7-1: Late Stage Cancer Compounds in Development for Major Indications, Distribution Estimates
Table 7-3: Recent NDA Activity: January 2011-July 2011
Table 7-4: Select New Approvals (NCE, Indications, Dosage, Formulations) ,2010-11
CHAPTER EIGHT: CORPORATE PROFILES
Figure 8-1: Late stage Cancer Therapies in Development for Leading Companies |
